A cost‐utility analysis of avelumab for metastatic Merkel cell carcinoma in Taiwan

BACKGROUND: Metastatic Merkel cell carcinoma (mMCC) has traditionally been managed with palliative chemotherapy regimens or best supportive care (BSC). Avelumab, a novel anti‐programmed death‐ligand 1 (PD‐L1) human monoclonal antibody for mMCC treatment, is being studied in the pivotal JAVELIN Merke...

Descripción completa

Detalles Bibliográficos
Autores principales: Chang, Wen‐Cheng, Lin, Amy Y., Hsu, Jason C., Wu, Chiao‐En, Goh, Connie, Chou, Patrick, Kuo, Kaitlin, Chang, Anne, Palencia, Roberto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8714552/
https://www.ncbi.nlm.nih.gov/pubmed/33934577
http://dx.doi.org/10.1002/cnr2.1399

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8714552/
https://www.ncbi.nlm.nih.gov/pubmed/33934577
http://dx.doi.org/10.1002/cnr2.1399

Ejemplares similares